IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candid…
Biotechnology
US, South San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 44.60 | 28.42 | 19.65 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -44.91 | 2.08 | 3.77 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 30.82 | 12.45 | 9.52 | |
| Cash | 15.60 | 9.30 | 8.05 | |
| Capex | -37.35 | -0.02 | -0.01 | |
| Free Cash Flow | -59.49 | -0.60 | -0.38 | |
| Revenue | inf | 0.00 | 0.06 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | 0.74 | |
| Operating Margin | inf | 0.00 | -10.68 | |
| ROA | 21.30 | -0.04 | -0.05 | |
| ROE | 22.61 | -0.04 | -0.05 | |
| ROIC | 32.42 | -0.05 | -0.08 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of IDYA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of IDYA is permitted for members.
6
Leverage & Liquidity